RNAi / siRNA Phase 2 Licensing Benchmarks
Deal economics across 5 transactions with 3 disclosed upfront payments. Primary-source-verified from SEC EDGAR, FTC filings, and direct research.
Median Upfront
$250M
3 deals with terms
Median Total Value
$1.0B
Upfront + milestones
Royalty Range
6%--15.3%
Average low--high
Deal Count
5
2018--2024
The median upfront payment for phase 2 rnai / sirna licensing deals is $250M, based on 3 deals with disclosed terms from 2018--2024. Total deal values (including milestones) reach a median of $1.0B. Royalty rates typically range from 6% to 15.3%. All data is primary-source-verified from SEC EDGAR, FTC pre-merger filings, and company press releases.
Representative Transactions
| Licensor | Licensee | Year | Upfront | Total Value |
|---|---|---|---|---|
| Alnylam Pharmaceuticals | Roche | 2023 | $310M | $2.5B |
| Alnylam Pharmaceuticals | Regeneron | 2024 | $250M | $1.4B |
| Ionis Pharmaceuticals | AstraZeneca | 2018 | $100M | $400M |
Full RNAi/siRNA phase-2 Comp Set
Get the complete analysis -- 3 deals with upfronts, milestones, royalties, and term structures.
Primary-source-verified from SEC EDGAR, FTC filings, and direct research
Run Your Own Analysis
Get a customized deal estimate for your specific rnai / sirna asset with our proprietary calculator.
Start CalculatingMethodology
This analysis draws from the Ambrosia Ventures proprietary deal database (1,600+ verified biopharma transactions, 2018--2024). All deal terms are primary-source-verified from SEC EDGAR (10-K, 10-Q, 8-K filings), FTC pre-merger notifications, FDA Orange Book, and company press releases. No secondary-source or scraped data is included. Medians are calculated from deals with disclosed financial terms only.